The RASSF1A Tumor Suppressor Regulates XPA-Mediated DNA Repair |
| |
| Authors: | Howard Donninger Jennifer Clark Francesca Rinaldo Nicholas Nelson Thibaut Barnoud M Lee Schmidt Katharine R Hobbing Michele D Vos Brian Sils Geoffrey J Clark |
| |
| Institution: | aDepartment of Medicine, J. G. Brown Cancer Center, Molecular Targets Program, University of Louisville, Louisville, Kentucky, USA;bDepartment of Biochemistry and Molecular Biology, University of Louisville, Louisville, Kentucky, USA;cDepartment of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA;dNational Cancer Institute, NIH, Bethesda, Maryland, USA |
| |
| Abstract: | RASSF1A may be the most frequently inactivated tumor suppressor identified in human cancer so far. It is a proapoptotic Ras effector and plays an important role in the apoptotic DNA damage response (DDR). We now show that in addition to DDR regulation, RASSF1A also plays a key role in the DNA repair process itself. We show that RASSF1A forms a DNA damage-regulated complex with the key DNA repair protein xeroderma pigmentosum A (XPA). XPA requires RASSF1A to exert full repair activity, and RASSF1A-deficient cells exhibit an impaired ability to repair DNA. Moreover, a cancer-associated RASSF1A single-nucleotide polymorphism (SNP) variant exhibits differential XPA binding and inhibits DNA repair. The interaction of XPA with other components of the repair complex, such as replication protein A (RPA), is controlled in part by a dynamic acetylation/deacetylation cycle. We found that RASSF1A and its SNP variant differentially regulate XPA protein acetylation, and the SNP variant hyperstabilizes the XPA-RPA70 complex. Thus, we identify two novel functions for RASSF1A in the control of DNA repair and protein acetylation. As RASSF1A modulates both apoptotic DDR and DNA repair, it may play an important and unanticipated role in coordinating the balance between repair and death after DNA damage. |
| |
| Keywords: | |
|
|
